ライフサイエンスコーパス: albuterol

1 eatment with a bronchodilator (180 microg of albuterol).

2 as-needed ICS treatment coadministered with albuterol.

3 er nasal suctioning and a trial of nebulized albuterol.

4 with COPD, including those "unresponsive" to albuterol.

5 /ml) and they lost the Qaw responsiveness to albuterol.

6 S)-enantiomer after long-term use of racemic albuterol.

7 d) was initiated 3 h before and 0.25 h after albuterol.

8 ing to viscoelastic tissues before and after albuterol.

9 ol, and -3.45 +/- 0.92 mm Hg at 20 min after albuterol.

10 after administration of both salmeterol and albuterol.

11 n tolerance to the bronchodilator effects of albuterol.

12 ing disorders before and after inhalation of albuterol.

13 ilar in both groups and did not change after albuterol.

14 scribed racemic albuterol is composed of (S)-albuterol.

15 oride and after reversal of provocation with albuterol.

16 the beta2AR-27 polymorphism and response to albuterol.

17 ht) was given orally with the second dose of albuterol.

18 EX, then challenged with media or 100 microM albuterol.

19 not changed by TNF-alpha or by any isomer of albuterol.

20 favorably to ephedrine, pseudoephedrine, or albuterol.

21 atients with COPD who received four puffs of albuterol.

22 and fenoterol and 100 times more potent than albuterol.

23 se dependent manner, but not by (S) or (R,S)-albuterol.

24 uction scores were lower for sheep receiving albuterol.

25 0 minutes after inhalation of 180 micro g of albuterol.

26 e) and 200 microg metered-dose inhaler (MDI) albuterol.

27 ephedrine, 0.250 with dobutamine, 0.148 with albuterol, 0.194 with fenoterol, and 0.212 with epinephr

28 (S)-Albuterol (1 and 10 muM) induced Ca2+ oscillations, reac

29 Racemic albuterol 10(-5) M, salmeterol 10(-6) M, and isoproteren

30 luid clearance was increased by both racemic albuterol 10(-6) M (14.5 +/- 3.0%, p <.05) and R-enantio

31 (S)-Albuterol (10 muM) increased inositol-1,4,5-trisphosphat

32 ) and significantly less than that caused by albuterol (10.4 +/- 1.7).

33 as also compared with unlabeled monodisperse albuterol (15-microg dose) and 200 microg metered-dose i

34 onsisted of baseline FEV1, pretreatment with albuterol 180 micrograms, postbronchodilator spirometry

35 lomethasone or placebo for each two puffs of albuterol (180 mug) needed for symptom relief.

36 gas for updraft nebulization of a mixture of albuterol 2.5 mg and ipratropium bromide 0.5 mg.

37 Additional aerosol treatments with albuterol 2.5 mg were given at 20, 40, and 120 mins afte

38 he children received a nebulized solution of albuterol (2.5 or 5 mg per dose, depending on body weigh

39 rine (100%) were 42% for fenoterol, 4.9% for albuterol, 2.5% for dobutamine, and 1.1% for ephedrine.

40 The IP(DVP) response to albuterol (400 microg by inhalation) was blunted in pati

41 volume pulse during intravenous infusion of albuterol (5 microg/min, DeltaRI(ALB)) and glyceryl trin

42 Albuterol (5.83 +/- 0.06 and 4.71 +/- 0.16) and fenotero

43 ity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M.

44 Medications included albuterol (81%), inhaled steroids (38%), cromolyn (35%),

45 acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical e

46 ter inhalation of a standard beta 2-agonist, albuterol (A).

47 In addition, application of albuterol, a selective beta(2)-adrenoceptor agonist, sig

48 Albuterol acted as a sequential fast-acting channel bloc

49 termined the response to increasing doses of albuterol administered by a MDI and cylindrical spacer t

50 Delivery of albuterol administered by a MDI and spacer on filter pla

51 We hypothesized that albuterol administered via continuous nebulization would

52 Albuterol administration was repeated at operating frequ

53 Prior to albuterol administration, NFEV(1) was significantly high

54 sed airway resistance, which was reversed by albuterol aerosol treatment.

55 inhaled technetium-99m-labeled monodisperse albuterol aerosols (30-microg dose) of 1.5-, 3-, and 6-m

56 ssfully radiolabeled and imaged monodisperse albuterol aerosols within the human lungs.

57 ol (ISO) (beta(1) approximately beta(2)) and albuterol (ALB) (beta(2)>beta(1)).

58 ent asthma should not be treated with rescue albuterol alone and the most effective treatment to prev

59 reducing exacerbations than is use of rescue albuterol alone.

60 e and homogeneous changes in spirometry with albuterol, along with greater changes in these measures

61 to tiotropium include a positive response to albuterol and airway obstruction, factors that could hel

62 Test aerosols of albuterol and antibiotics were compared.

63 e observed beginning with the lowest dose of albuterol and continuing throughout the dose-response as

64 thma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decre

65 IP(DVP), whereas systemic administration of albuterol and GTN produced dose-dependent reductions in

66 gonists with intermediate strengths, such as albuterol and salmeterol, stimulate GRK site phosphoryla

67 on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 2

68 re and after administration of 180 microg of albuterol, and a positive response was considered an inc

69 re and up to 4 h after inhalation of racemic albuterol, and determined the unchanged R/S ratio in uri

70 adenosine monophosphate (cAMP), salmeterol, albuterol, and isoproterenol in normal rat lung.

71 g SCF were premedicated with antihistamines, albuterol, and pseudoephedrine.

72 assess lower respiratory tract deposition of albuterol, and show that MDIs are more efficient for aer

73 e presence of the short-acting beta2-agonist albuterol, and the long-acting beta2-agonists formoterol

74 and ICAM-1 were not changed by any isomer of albuterol as measured by real time RT-PCR.

75 aily beclomethasone with beclomethasone plus albuterol as rescue (combined group); twice daily beclom

76 twice daily beclomethasone with placebo plus albuterol as rescue (daily beclomethasone group); twice

77 ); and twice daily placebo with placebo plus albuterol as rescue (placebo group).

78 twice daily placebo with beclomethasone plus albuterol as rescue (rescue beclomethasone group); and t

79 f Spiros and Ventolin (90- and 270-microgram albuterol base).

80 ured plasma levels of unchanged (R)- and (S)-albuterol before and up to 4 h after inhalation of racem

81 ects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as n

82 at Met772-AC9 is associated with an improved albuterol bronchodilator response in asthmatics was inve

83 cohort of 203 527 patients who began taking albuterol but did not receive antipsychotic medication.

84 The effects of albuterol but not GTN on IP(DVP) were attenuated by N(G)

85 Although albuterol, but not the two placebo interventions, improv

86 5) decreases in Raw and tissue damping after albuterol, but tissue elastance decreased only in the Ty

87 response to regular versus as-needed use of albuterol by genotyping the 190 asthmatics who had parti

88 n minutes after administration of 180 microg albuterol by metered dose inhaler, mean Qaw increased by

89 m bromide with the second and third doses of albuterol; children in the control group received 2.5 ml

90 FR during treatment with regularly scheduled albuterol compared with placebo (14 L/min [95% CI 3 to 2

91 Filters were rinsed with water and albuterol concentrations determined by high performance

92 The filter was rinsed with water and albuterol concentrations were determined by high-perform

93 ontinuous nebulization group, or d) 40 mg of albuterol continuous nebulization group (n=5 animals per

94 e continuous nebulization group, c) 20 mg of albuterol continuous nebulization group, or d) 40 mg of

95 ferent from background rates observed in the albuterol control group.

96 After albuterol, control subjects showed no change in spiromet

97 bo-controlled trials have shown that inhaled albuterol decreases the duration of cough in adults with

98 used to determine significant differences in albuterol delivered or lost among the operating frequenc

99 These in vitro results suggest albuterol delivery by MDI in a pediatric model of HFOV i

100 Albuterol delivery from a MDI was increased when the ven

101 ined the effect of various He-O2 mixtures on albuterol delivery from metered-dose inhalers (MDIs) and

102 idity, and spontaneous respiratory effort on albuterol delivery in a model of the trachea and bronchi

103 Albuterol delivery showed a linear correlation with both

104 Albuterol delivery to the lower respiratory tract was de

105 Albuterol delivery to the lung simulator was <1% of the

106 the nebulizer was operated with O2, greater albuterol delivery was achieved when the ventilator circ

107 Albuterol delivery was significantly (p < or = .05) grea

108 ions and with a frequency of 10 breaths/min, albuterol delivery with CMV (VT, 800 ml; 30.3 +/- 3.4%),

109 anics and a 6.0-mm endotracheal tube improve albuterol delivery.

110 greater bronchodilation than 200 microg MDI albuterol (deltaFEV1 [ml]: 6 microm [551], 3 microm [457

111 likely due to the low-density gas improving albuterol deposition in the distal airways.

112 We conclude that 180 micrograms albuterol does not prevent excessive bronchoconstriction

113 demonstrates that, in emergency situations, albuterol does not relieve acute airway obstruction in a

114 In this tissue, albuterol does not stimulate exocytosis either in vivo o

115 The percentage albuterol dose lost in the circuit's expiratory limb and

116 statistically significant differences in the albuterol dose response following salmeterol or placebo.

117 Albuterol, due to its bronchodilatory and anti-inflammat

118 gned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or

119 In the remainder, albuterol, even in high doses, has little effect for day

120 d in the circuit's expiratory limb collected albuterol exiting the endotracheal tube and any albutero

121 ling efficiency, with ephedrine, dobutamine, albuterol, fenoterol, and epinephrine giving 0, 7, 17, 4

122 ditional inhaled short-acting beta2-agonists albuterol, fenoterol, and terbutaline provide rapid as-n

123 corticosteroids, post 180 microg aerosolized albuterol, FEV(1) was 74 +/- 23% predicted and FEV(1)/FV

124 erformed before and at 5-min intervals after albuterol for 80 min.

125 (S)-albuterol (the inactive isomer) or (R,S)-albuterol for 90 minutes before adding 2 ng/ml TNF-alpha

126 In conclusion, four puffs of albuterol given by a MDI and spacer provided the best co

127 Compared with saline and control groups, the albuterol groups had lower pause and peak inspiratory pr

128 efficiency, i.e. epinephrine >/= fenoterol > albuterol > dobutamine > ephedrine.

129 terol = fenoterol > terbutaline = zinterol = albuterol > salmeterol > dobutamine > or = ephedrine.

130 d on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were rand

131 tudy Arg Arg patients who had regularly used albuterol had a morning peak expiratory flow 30.5 +/- 12

132 Racemic albuterol has been one of the most widely used beta2-adr

133 Inhaled albuterol, however, resulted in significant improvement

134 day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of h

135 Continuous nebulization of albuterol improves pulmonary function via improved airwa

136 w (Qaw) and FEV (1) before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients

137 xpression was significantly inhibited by (R)-albuterol in a dose dependent manner, but not by (S) or

138 ncrease in Qaw and its hyporesponsiveness to albuterol in asthmatic subjects may be consequences of a

139 iability in response to therapeutic doses of albuterol in children.

140 tes to individual differences in response to albuterol in Latinos, notably in SLC genes that include

141 no decline in peak flow with regular use of albuterol in patients who were homozygous for glycine at

142 Improvements in FEV(1) after albuterol in patients with COPD are due to reduction of

143 Currently we have completed a pilot study of albuterol in patients with late-onset Pompe disease alre

144 thma severity and bronchodilator response to albuterol in Puerto Ricans and Mexicans with asthma.

145 05)-indicating preferential retention of (S)-albuterol in the lung.

146 Both (S)-and (R,S)-albuterol increased [Ca2+]i at concentrations of >10 pM

147 Albuterol increased Qaw by 27 +/- 3% in the control subj

148 ) was significantly (p < 0.01) reduced after albuterol inhalation (60.6 +/- 22.2 cm H(2)O/L/s) but pr

149 rolled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo.

150 We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects

151 However, post-albuterol inhalation, FEV(1) increased more than NFEV(1)

152 V1, 54 to 91% of predicted) before and after albuterol inhalation.

153 halation, and it is significantly reduced by albuterol inhalation.

154 vention did not differ significantly for the albuterol inhaler (50% improvement), placebo inhaler (45

155 were also given liquid dextromethorphan and albuterol inhaler with a spacer.

156 ents with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture,

157 ost patients (81%) reported benefit from the albuterol inhaler.

158 plications because 50% of prescribed racemic albuterol is composed of (S)-albuterol.

159 n dyspnea in patients with COPD with inhaled albuterol is in part due to increased diaphragmatic cont

160 treatment of ASM cultures with beta-agonists albuterol, isoproterenol, or salmeterol (100 nM to 10 mu

161 Serum albuterol levels (+/- SEM) quantitated by high-performan

162 etered-dose inhaler (MDI), we measured serum albuterol levels after administration by a MDI and space

163 Albuterol lost in the expiratory limb ranged from 3.28%

164 uterol exiting the endotracheal tube and any albuterol lost, respectively.

165 Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/A

166 The results also suggest that (S)-albuterol may cross-react with muscarinic receptors.

167 a Ca2+ agonist in airway smooth muscle, (S)-albuterol may have profound clinical implications becaus

168 to week 48 in mean daily number of puffs of albuterol, mean total asthma symptom score, and mean ove

169 In vitro, DEX treatment induced albuterol-mediated glandular exocytosis (p < 0.04), and

170 ial scrapings (p < 0.04), but did not induce albuterol-mediated glandular secretion.

171 ed corticosteroids as rescue medication with albuterol might be an effective step-down strategy for c

172 d at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-d

173 bjects received saline or BDP for 3 d before albuterol nasal provocation.

174 had a significantly higher heart rate after albuterol nebulization compared with the control group.

175 We studied the spirometric effects of albuterol nebulized with heliox during emergency room vi

176 lude that during acute asthma exacerbations, albuterol nebulized with heliox leads to a more signific

177 rty-five patients were randomized to receive albuterol nebulized with oxygen (control) versus heliox

178 improvement in spirometry when compared with albuterol nebulized with oxygen.

179 second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-lif

180 ts had reversibility in FEV1 after nebulized albuterol of 15% or more and a mean postbronchodilator F

181 = 0.012) than Arg/Arg patients who had used albuterol on an as needed basis.

182 lbuterol regularly but not in those who used albuterol on an as-needed basis.

183 onsiveness, we determined the effects of (S)-albuterol on intracellular Ca2+ concentration ([Ca2+]i)

184 The effects of albuterol on IP(DVP) are mediated in part through the ni

185 L IMPLICATION: The suppressive effect of (R)-albuterol on neural ICAM-1 expression may be an addition

186 atients randomly received inhaled placebo or albuterol on the first test day and the alternative medi

187 ranolol blocked the inhibitory effect of (R)-albuterol on TNF-alpha-induced ICAM-1 expression.

188 isomers (enantiomers) of beta(2)AR agonists, albuterol or formoterol.

189 Both groups received albuterol or levalbuterol prior to each study drug dose.

190 Eleven patients with COPD inhaled albuterol or placebo in a double-blind randomized manner

191 Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over d

192 r on vasodilator responses to acetylcholine, albuterol, or levcromakalim.

193 resistance occurred after administration of albuterol (p < 0.001).

194 n the group that received only four puffs of albuterol (p < 0.003).

195 re maintained for 6 h after the last dose of albuterol (p < 0.05).

196 to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tio

197 Albuterol produced a decrease in dyspnea (5 +/- 2 to 4 +

198 Compared with placebo, albuterol produced an increase in inspiratory capacity (

199 The (R)-enantiomer of racemic albuterol produces bronchodilation, whereas the (S)-enan

200 proved FEV(1) in these patients with asthma, albuterol provided no incremental benefit with respect t

201 sitive, and in these patients 5 to 7.5 mg of albuterol provides optimal treatment.

202 oint [CI, 0.15 to 0.43]), reduced mean daily albuterol puffs (-0.27 puff/d [CI, -0.49 to -0.04 puff/d

203 Albuterol recovery at 20 minutes after histamine challen

204 so declined in the Arg/Arg patients who used albuterol regularly but not in those who used albuterol

205 or arginine at B(2)-AR-16 (Arg/Arg) who used albuterol regularly.

206 In conclusion, albuterol relieves dyspnea and enhances respiratory musc

207 To determine the dose of albuterol required to terminate acute episodes of asthma

208 and 86.8%, respectively; P=0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per we

209 scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared

210 inhaled corticosteroids were taken with each albuterol rescue use.

211 .3 times (1.3-4.2) more likely to respond to albuterol, respectively.

212 d clinical features, airflow limitation, and albuterol responsiveness in adults acutely ill with asth

213 nsistent with this AC9 polymorphism altering albuterol responsiveness in the context of concomitant i

214 r (beta(2)AR) may modify asthma severity and albuterol responsiveness.

215 ong the 39 patients who completed the study, albuterol resulted in a 20% increase in FEV(1), as compa

216 The disposition of albuterol's enantiomers with a MDI and holding chamber w

217 Albuterol (salbutamol) and glyceryl trinitrate (GTN) wer

218 Inhaled albuterol should be prescribed for patients with mild as

219 ich all patients returned to using as-needed albuterol, so that by the end of the study Arg Arg patie

220 ressing Met772 had a significantly increased albuterol-stimulated adenylyl cyclase response (approxim

221 wer after treatment with the partial agonist albuterol, suggesting a correlation between the efficien

222 ator to produce (99m)Tc-labeled monodisperse albuterol sulfate aerosols of 1.5-, 3-, and 6- micro m m

223 Four formulations of albuterol sulfate and budesonide in sieved and milled la

224 examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlist

225 , evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life.

226 l treatment solutions were premedicated with albuterol sulfate.

227 at Puerto Ricans with asthma respond less to albuterol than do Mexicans with asthma.

228 had lower morning PEFR during treatment with albuterol than during the placebo period, when albuterol

229 Cells were incubated with either (R)-albuterol (the active isomer), (S)-albuterol (the inacti

230 ither (R)-albuterol (the active isomer), (S)-albuterol (the inactive isomer) or (R,S)-albuterol for 9

231 ral or intravenous administration of racemic albuterol, the (R)- enantiomer is metabolized several ti

232 itude but was more prolonged than that after albuterol, the greatest mean change being -2.74 +/- 0.89

233 After nebulized albuterol, the mean TGV decreased to 96.4 +/- 1.3% predi

234 fficacy in an open label study of adjunctive albuterol therapy in patients with late-onset Pompe dise

235 ice with Pompe disease following addition of albuterol therapy.

236 We hypothesized that targeting albuterol to regional airways by altering aerosol partic

237 Spiros actuation delivers 1.12 times as much albuterol to the airways as one Ventolin actuation (90%

238 in inhalers deliver comparable quantities of albuterol to the airways.

239 In terms of delivery of albuterol to the lungs, we compared an alternative deliv

240 Six of 28 albuterol-treated infants demonstrated increases in FEF(

241 Following albuterol Treatment 1, the median change in forced expir

242 ll subjects responded promptly to additional albuterol treatment, and no subject developed refractory

243 to 2.82 +/- 1.59, p < 0.001) after the first albuterol treatment.

244 Patients received nebulized albuterol treatments every 20 min with a maximum of thre

245 Three consecutive albuterol treatments were given to each group.

246 ores (-1.0 +/- 0.1 vs. -0.6 +/- 0.1), rescue albuterol use (-3.3 +/- 0.2 vs. -1.9 +/- 0.2 puffs/d), a

247 with moderate-to-severe asthma with frequent albuterol use and nighttime awakenings at least once wee

248 s the characterization of effects of regular albuterol use in patients with genetic variations in the

249 During the study, as-needed albuterol use was discontinued and ipratropium bromide w

250 During the run-in period, when albuterol use was kept to a minimum, patients with the A

251 buterol than during the placebo period, when albuterol use was limited (-10 L/min [-19 to -2]; p=0.02

252 ome spirometry, histamine challenge, inhaled albuterol use, and asthma symptom scores.

253 re function had more asthma symptoms, rescue albuterol use, and FEV(1) reversal (P < 0.001, 0.03, and

254 FEV1, peak expiratory flow, symptoms, rescue albuterol use, and quality of life scores, also did not

255 duced asthma symptom scores and supplemental albuterol use, and significantly increased the percentag

256 mptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measu

257 I scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, control

258 ning the effects of regular versus as needed albuterol use.

259 c receptor affects the long-term response to albuterol use.

260 duled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chro

261 responsiveness to the inhaled beta-agonist, albuterol, using changes in maximal expiratory flows.

262 s were used to administer 2000 micrograms of albuterol, using either a collapsible or a rigid spacer.

263 at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0

264 .M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5 and 2.6% with placebo (p = 0.0

265 ificantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M.

266 was significantly greater (p < 0.05) in the albuterol versus placebo group for FEV(0.5) (2.2% versus

267 han 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurr

268 The R/S ratio in urine at 0.5 h after albuterol was > 1, reflecting the higher plasma level of

269 ease in airway resistance with four puffs of albuterol was comparable to that observed with cumulativ

270 Albuterol was equally efficacious in both populations an

271 In 34% of participants, albuterol was ineffectual.

272 sus baseline), and the Qaw responsiveness to albuterol was restored ( +21 +/- 2%; p < 0.05) in the as

273 teroid) and a negative control drug (inhaled albuterol) was also assessed.

274 1 after cumulative doubling doses of inhaled albuterol were assessed after a 2-wk beta-agonist washou

275 e validation data showed that technetium and albuterol were coassociated on each impactor stage for a

276 Formoterol and albuterol were equally efficacious.

277 Four, eight, and 16 puffs of albuterol were given at 15-min intervals.

278 +/- SE) FEV(1) and FEV(1) responsiveness to albuterol were not affected by FP.

279 In contrast, bronchodilator responses to albuterol were similar in eosinophilic and noneosinophil

280 hort-term bronchodilator response to inhaled albuterol were small and judged to be clinically unimpor

281 centage change in FEV(1) after 180 microg of albuterol, were adjusted to account for sex, age, height

282 The EPR was blocked by cromoglycate and albuterol, whereas the LPR was abolished by cromoglycate

283 sponse is in a stark contrast to that of (R)-albuterol, which decreased [Ca2+]i.

284 In summary, administration of albuterol with a MDI achieved a profile of serum levels

285 rdingly, 10 healthy subjects inhaled racemic albuterol with a MDI alone and with a MDI and holding ch

286 nantiomer disposition after inhaling racemic albuterol with a metered-dose inhaler (MDI) is not known

287 sters were used to administer 2000 microg of albuterol with a spacer.

288 ffects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in